Cyclohexanecarboxamide, N-[3-(1-cyclopropyl-1H-pyrazol-4-yl)phenyl]-4-hydroxy-N-[[trans-4-(4-methoxy-3-methylphenyl)cyclohexyl]methyl]-, trans-

Request For Quotation
Cyclohexanecarboxamide, N-[3-(1-cyclopropyl-1H-pyrazol-4-yl)phenyl]-4-hydroxy-N-[[trans-4-(4-methoxy-3-methylphenyl)cyclohexyl]methyl]-, trans- Basic information
Product Name:Cyclohexanecarboxamide, N-[3-(1-cyclopropyl-1H-pyrazol-4-yl)phenyl]-4-hydroxy-N-[[trans-4-(4-methoxy-3-methylphenyl)cyclohexyl]methyl]-, trans-
Synonyms:Cyclohexanecarboxamide, N-[3-(1-cyclopropyl-1H-pyrazol-4-yl)phenyl]-4-hydroxy-N-[[trans-4-(4-methoxy-3-methylphenyl)cyclohexyl]methyl]-, trans-;omesdafexor
CAS:2244440-85-3
MF:C34H43N3O3
MW:541.72
EINECS:
Product Categories:
Mol File:2244440-85-3.mol
Cyclohexanecarboxamide, N-[3-(1-cyclopropyl-1H-pyrazol-4-yl)phenyl]-4-hydroxy-N-[[trans-4-(4-methoxy-3-methylphenyl)cyclohexyl]methyl]-, trans- Structure
Cyclohexanecarboxamide, N-[3-(1-cyclopropyl-1H-pyrazol-4-yl)phenyl]-4-hydroxy-N-[[trans-4-(4-methoxy-3-methylphenyl)cyclohexyl]methyl]-, trans- Chemical Properties
Boiling point 735.5±60.0 °C(Predicted)
density 1.24±0.1 g/cm3(Predicted)
pka14.96±0.40(Predicted)
form Solid
color White to off-white
Safety Information
MSDS Information
Cyclohexanecarboxamide, N-[3-(1-cyclopropyl-1H-pyrazol-4-yl)phenyl]-4-hydroxy-N-[[trans-4-(4-methoxy-3-methylphenyl)cyclohexyl]methyl]-, trans- Usage And Synthesis
UsesOmesdafexor (MET642) is an oral FXR agonist. Omesdafexor can improve colitis induced by adoptive T cell transfer，promote intestinal antimicrobial function, barrier function and inhibit inflammation [1][2][3].
in vivo

Omesdafexor (0.03-0.3 mg/kg, orally, once daily, four weeks) with tofacitinib can synergistically improve colitis[2].
Omesdafexor (0.1-1 mg/kg, orally, once daily, four weeks) can improve colitis induced by adoptive T cell transfer[3].

Animal Model:Colitis mouse model [2]
Dosage:0.03, 0.3 mg/kg; once a day; four weeks
Administration:Oral
Result:Reduced the number of innate immune cells in mesenteric lymph nodes, but not T cells, and could synergistically improve colitis when used in combination with tofacitinib.
Animal Model:Transplanting CD4+CD45RBhi T-cells to recipient C.B-17 SCID mice[3]
Dosage:0.1, 0.3, 1 mg/kg; once a day; four weeks
Administration:Oral
Result:Improved adoptive T cell transfer-induced colitis, promoted intestinal antimicrobial function, barrier function and inhibited inflammation.
References[1] https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl127.pdfsfvrsn=8544ca1e_3&download=true
[2] Xueqing Liu, et al. COMBINATION OF FXR AGONIST MET642 WITH TOFACITINIB EXHIBITS SYNERGISTIC EFFECTS IN IMPROVING COLITIS IN ADOPTIVE T-CELL TRANSFER IBD MODEL. METACRINE.
[3] Xueqing Liu, et al. P153 MET642, AN ORAL FXR AGONIST, IMPROVES COLITIS INDUCED BY ADOPTIVE T-CELL TRANSFER. Volume 158, Issue 3, Supplement S11February 2020.
Cyclohexanecarboxamide, N-[3-(1-cyclopropyl-1H-pyrazol-4-yl)phenyl]-4-hydroxy-N-[[trans-4-(4-methoxy-3-methylphenyl)cyclohexyl]methyl]-, trans- Preparation Products And Raw materials
Tag:Cyclohexanecarboxamide, N-[3-(1-cyclopropyl-1H-pyrazol-4-yl)phenyl]-4-hydroxy-N-[[trans-4-(4-methoxy-3-methylphenyl)cyclohexyl]methyl]-, trans-(2244440-85-3) Related Product Information
Methanone, [(2S)-5-(cyclobutyloxy)-3,4-dihydro-2-methyl-6-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-1(2H)-quinolinyl]cyclopropyl- Cyclohexanecarboxamide, N-[3-(1-cyclopropyl-1H-pyrazol-4-yl)phenyl]-4-hydroxy-N-[[trans-4-(4-methoxy-3-methylphenyl)cyclohexyl]methyl]-, trans- Forskolin T0901317 Anti-cancer compound library Ursodeoxycholic acid